Sanofi ends Phase 1 trial of STAT6 degrader partnered with Nurix
Sanofi told Nurix it is stopping development of SAR448272 and shutting down the program, cutting off related milestone and royalty payments to Nurix.
SEC filing
2 stories
Sanofi told Nurix it is stopping development of SAR448272 and shutting down the program, cutting off related milestone and royalty payments to Nurix.
SEC filing
Nurix dosed its first patient in a registrational Phase 3 CLL trial for bexobrutideg, discontinued NX-2127, and ended the quarter with $1.1 billion in cash after closing its Roche collaboration.
SEC filing